Printer Friendly

SBIR GRANT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO AIDS THERAPY

 SBIR GRANT AWARDED FOR APPLICATION
 OF MEDISPERSE TECHNOLOGY TO AIDS THERAPY
 SOMERVILLE, N.J., Dec. 3 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today that a Small Business Innovative Research (SBIR) Phase I Grant in the amount of $50,000 has been awarded by the National Institute of Allergy and Infectious Diseases for the application of Medisperse technology to improved inhalation therapy of AIDS-related infections.
 Over 80 percent of AIDS patients suffer from AIDS-related infections, the most common of which is Pneumocystis carinii pneumonia. The high mortality rate of these infections defines a need for improved treatment and prophylaxis. Inhalation therapy plays an important role in delivery of current therapeutic compounds but current formulations are often associated with lung irritation and other side effects.
 Under the grant, the feasibility of using Medisperse technology to improve inhalation therapy will be evaluated. If this proves feasible, improved formulations of currently available therapeutic compounds for AIDS-related infections will be developed for further testing. The patented Medisperse process produces uniform suspensions of drug particles. By altering the conditions of the process, the size and distribution of these particles can be precisely controlled.
 "Appropriately sized Medisperse particles may improve the amount of drug that reaches the deep lung," said Michael R. Violante, Ph.D., inventor of the technology and a managing director of Medisperse, L.P., "and could provide more effective and convenient therapy for AIDS patients suffering from AIDS-related infections."
 Medisperse L.P., a joint venture between UNIMED, Inc. and Sterilization Technical Services, Inc., (Rochester, N.Y.), a privately owned contract services and technology development company, is commercializing a novel drug formulation and delivery technology with potential application to both therapeutics and diagnostic imaging agents.
 UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients. The company has brought two pharmaceuticals to market and has a portfolio of drugs in development.
 -0- 12/3/91
 /CONTACT: Charles P. Harrison, president of UNIMED, 908-526-6894/
 (UMED) CO: Unimed, Inc. ST: New Jersey IN: MTC SU:


PS -- NY008 -- 8622 12/03/91 09:11 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:350
Previous Article:DETROIT COMMUNITY LEADERS TO ANNOUNCE POSITION ON PROPOSED DETROIT STADIUM BALLOT QUESTION
Next Article:MULTIFOODS COMPLETES SALE OF NORTH AMERICAN AG OPERATIONS
Topics:


Related Articles
SBIR GRANT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO AIDS THERAPY
VERTEX PHARMACEUTICALS RECEIVES NATIONAL SCIENCE FOUNDATION GRANT TO DEVELOP NOVEL ENZYME TECHNOLOGY
GOVERNMENT CONTRACT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO FORMULATE CANCER AND AIDS DRUGS
UNIMED REPORTS REVENUE GROWTH OF 46 PERCENT IN FISCAL FIRST QUARTER
LIDAK PHARMACEUTICALS RECEIVES FEDERAL GRANT FOR STUDIES OF POTENTIAL CANCER THERAPY
IDEC PHARMACEUTICALS AWARDED PHASE II GRANT FROM NIH TO FURTHER DEVELOPMENT OF AIDS THERAPEUTICS
HAUSER EXPANDS AIDS RELATED RESEARCH WITH THIRD NIH GRANT
SBIR GRANT FROM NATIONAL CANCER INSTITUTE PUTS GENETRONICS' TOTAL SBIR FUNDING OVER $1 MILLION
CUBIST PHARMACEUTICALS INC. RECEIVES TWO SBIR PHASE II GRANTS TOTALING $1.3 FOR THE DEVELOPMENT OF NOVEL ANTI-INFECTIVES
Progenics Pharmaceuticals Awarded $1.1 Million in NIH Grant Funding to Develop Novel HIV Therapeutics

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters